Rethinking Distribution: The Need For Adaptive Distribution Partners For Cell And Gene Therapies

The transition from traditional inventory to order-based fulfillment represents a fundamental shift in how advanced therapies reach patients. Unlike standard pharmaceuticals, cell and gene therapies demand a distribution framework built on specialized expertise and operational agility. A partner’s ability to customize workflows and manage unpredictable reimbursement timelines often determines the ultimate speed of a product launch. By integrating sophisticated technology with specialized pharmacy support, manufacturers can reduce administrative friction for healthcare providers while maintaining product integrity throughout the cryogenic supply chain.

Establishing these strategic alignments before launch ensures that the complex journey from manufacturer to patient remains seamless and reliable. For a deeper look at optimizing your commercial strategy, access the full article.